Market Overview

Gilead Announces Positive Hepatitis C Data

Gilead Sciences (NASDAQ: GILD) announced Saturdayinterim data from the
ongoing Phase 2 ELECTRON study examining a 12-week course of therapy
with the investigational nucleotide sofosbuvir (formerly referred to as
GS-7977), the NS5A inhibitor GS-5885 and ribavirin in patients with
genotype 1 chronic hepatitis C virus (HCV) infection. Among
treatment-naïve patients receiving this combination, 100 percent
(n=25/25) remained HCV RNA undetectable four weeks after completing
therapy (SVR4). These data will be presented on Tuesday, November 13th
at the 63rd annual meeting of the American Association for the Study of
Liver Diseases (The Liver Meeting 2012) in Boston.

“These results indicate that adding GS-5885 to sofosbuvir-based regimens
may enhance SVR rates, potentially offering HCV genotype 1 infected

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (GILD)

Around the Web, We're Loving...

Get Benzinga's Newsletters